


product innovation to address critical unmet needs


Frank Leonard
Chief Development Officer
Novocure

potential to further improve efficacy through extended time on therapy and increased intensity

electric field intensity¹



time on therapy in ef-14 study²




*Based on amount of time Optune was turned on and providing therapy over the course of a month. This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6). †Approximation, based on monthly usage; vs TMZ alone.


1. Ballo MT, Urman N, Lavy-Shahaf G, Bomzon Z, Toms S. Correlation of Tumor Treating Fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the Phase 3 EF-14 randomized trial. Int J Radiat Oncol Biol Phys. 2019; 104(5): 1106-1113. doi: 10.1016/j.ijrobp.2019.04.008

2. Ram Z, Kim C.Y, Nicholas GA and Toms S on behalf of EF-14 investigators. Compliance and treatment duration predict survival in a phase 3 EF-14 trial of Tumor Treating Fields with temozolomide in patients with newly diagnosed glioblastoma. Presented at: 2017 Society for Neuro Oncology, November 16-19, 2017, San Francisco, CA. Oral presentation ACTR-27.


product innovation intended to improve efficacy
and patient ease of use



field generator




arrays



software applications

current product development programs




**flexible torso
array**

in progress



**gen 2.0 torso
device**

*FDA submission
expected Q4 2020*



**high-intensity
head array**

EF-33 trial underway



**MAXPOINT™
planning software**

beta testing underway

34 new patent applications YTD in 2020

EF-33 pilot trial underway



**high-intensity
head array**

- designed to increase field intensity
- enrolling 25 patients
- safety and effectiveness will be compared to EF-11 control data
- final data expected 2022

MyLink has the potential to improve patient safety and improve device use

virtual start
included remote
MyLink training

compliance
data within
24 hours



treatment gaps
noticed and
customized support
plan created

patient achieved
targeted compliance
rate

MyLink


MyLink launched in May 2020



MyLink

- eliminates device support specialist visits
- successful pilot launch
- expedited release in response to pandemic
- improves patient support

product roadmap will prioritize impact on both dose and ease of use



- next gen arrays designed to be more flexible and deliver higher intensities

- patient-centered software designed to support larger patient populations in multiple indications

- Device 3.0 designed to optimize the use of electric fields to treat tumors

aligned product
development
and business
development together

clinical collaboration with MSD* for phase 2 pilot trial in non-small cell lung cancer



KEYNOTE B36

Lung Cancer

important expansion of lung cancer program into first-line non-small cell lung cancer with a global leader in oncology

- plan to conduct phase 2 pilot study of Tumor Treating Fields with anti-PD-1 therapy Keytruda®
- expect to enroll 66 patients in the U.S. with advanced or metastatic, intrathoracic non-small cell lung cancer
- primary endpoint: objective response rate (ORR)
- expected to begin in H1 2021